SLC5A2 and heart failure: In particular, the SGLT2 inhibitors (SGLT2i) have demonstrated robust benefits in terms of the prevention of heart failure (HF) and the reduction in cardiovascular mortality, which was the first evidence for prevention of major cardiovascular events by anti-diabetic medications.